Across TCGA pan-cancer cohorts, MFAP3L Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MFAP3L data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MFAP3L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MFAP3L expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, BLCA, and COAD are the cancer types where MFAP3L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.250	0.692	.009	18	view →
BLCA	DFS	Median	All	0.097	0.626	<.001	18	view →
COAD	OS	Median	IV	0.056	0.649	<.001	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.033	10	view →
STAD	OS	Median	All	0.250	0.729	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: MFAP3L tumor-vs-normal RNA expression · all MFAP3L data types